GEHC vs NNOX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GEHC and NNOX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GEHC and NNOX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

GE HealthCare is the medical technology business spun off from the former General Electric conglomerate as an independent company. It is one of the world's largest makers of medical imaging and diagnostic equipment. Its product portfolio spans MRI, CT, X-ray, ultrasound, and molecular imaging systems, plus contrast agents and radiopharmaceuticals used in scans, patient monitoring devices, and a growing suite of healthcare software and AI tools that help clinicians interpret images and manage care. GE HealthCare makes money by selling these large imaging systems to hospitals and clinics, and importantly through recurring revenue from service contracts, maintenance, software, and consumables like contrast media. With a large installed base of equipment worldwide, the company benefits from steady demand for diagnostics, an aging global population, and the growing role of AI in radiology. Headquartered in Chicago, it serves healthcare providers across developed and emerging markets and competes among the top global medical imaging vendors.

Full GEHC guide

Nano-X Imaging Ltd is a medical-imaging technology company, headquartered in Israel, developing and commercializing a new approach to X-ray imaging. Its core innovation is a digital, semiconductor-based X-ray source (a cold-cathode, MEMS-style emitter) that the company positions as a lower-cost, more compact alternative to the traditional hot-filament X-ray tubes used across the industry. That source powers the Nanox.ARC and Nanox.ARC X, multi-source digital tomosynthesis systems that produce 3D-style tomographic images and have received FDA 510(k) clearance for a range of musculoskeletal and other indications. In February 2026 the company also received FDA clearance for TAP2D, a cloud-enabled feature that generates a 2D image from a single 3D tomosynthesis scan.

Full NNOX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GEHC drivers: Large installed base and recurring revenue; AI and software in imaging.
• NNOX drivers: Differentiated imaging technology; FDA clearances and the Nanox.ARC roadmap.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: GE HealthCare sells capital equipment to hospitals, whose budgets can tighten during economic or fiscal pressure, delaying purchases. For NNOX, the dominant risk is that Nano-X is early-commercial and unprofitable, with tiny revenue relative to its spending and ongoing cash burn, so it may need to raise additional capital that could dilute existing shareholders.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GEHC if you believe its drivers more; NNOX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GEHC and NNOX guides.

GEHC. GE HealthCare is valued as a defensive medical technology company with a large installed base and recurring service and consumables revenue. Investors weigh steady diagnostics demand and AI-driven product upgrades against competition and hospital capital-spending cycles. The valuation reflects a stable healthcare franchise with moderate growth and the optionality of expanding software and higher-margin businesses.

NNOX. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Nano-X has minimal revenue and no profits, traditional earnings multiples are not meaningful, and the stock is valued largely on the perceived potential of its technology and partnerships. The most important numbers to watch are cash on hand versus quarterly burn (which together imply how long the company can operate before needing to raise money) and the pace of actual system installations, not any single revenue print.

Headline figures (approximate, early 2026): GEHC shows revenue (ttm) ~$19 to 21 billion, operating margin ~mid teens percent, net income (ttm) ~$2 billion or more, recurring revenue mix ~meaningful service and consumables; NNOX shows q1 2026 revenue about $4.3 million, up year over year but still very small, profitability not profitable; the company operates at a loss and burns cash, cash position about $44.2 million as of March 31, 2026, down from roughly $60 million at year-end 2025, operating cash flow (q1 2026) roughly negative $14 million in the quarter.

GEHC and NNOX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GEHC and NNOX exposure against your real portfolio. It is not an investment adviser.